Angiogenesis in cancer and other diseases

[1]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[2]  L. Ellis,et al.  Chemotherapeutic drugs—more really is not better , 2000, Nature Medicine.

[3]  R. D'Amato,et al.  Genetic heterogeneity of angiogenesis in mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  R. Jain,et al.  Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. , 2000, Cancer research.

[5]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[6]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[7]  J. Isner,et al.  Stem cell therapy and gene transfer for regeneration , 2000, Gene Therapy.

[8]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[9]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[10]  R. Jain,et al.  Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. , 2000, Cancer research.

[11]  P. Carmeliet,et al.  Transgenic mouse models in angiogenesis and cardiovascular disease , 2000, The Journal of pathology.

[12]  I. Buschmann,et al.  The pathophysiology of the collateral circulation (arteriogenesis) , 2000, The Journal of pathology.

[13]  R. Jain,et al.  Leaky vessels? Call Ang1! , 2000, Nature Medicine.

[14]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[15]  P. Carmeliet,et al.  PR39, a peptide regulator of angiogenesis , 2000, Nature Medicine.

[16]  S. Rafii,et al.  Circulating endothelial precursors: mystery, reality, and promise. , 2000, The Journal of clinical investigation.

[17]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[18]  M. Rabinovitch.  Pulmonary hypertension: pathophysiology as a basis for clinical decision making. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  P. Carmeliet.  Developmental biology: Controlling the cellular brakes , 1999, Nature.

[20]  C. Compton,et al.  Tumor–host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1 , 1999, Nature Medicine.

[21]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[22]  P. Carmeliet,et al.  Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.

[23]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[24]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[25]  Willem Flameng,et al.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 1999, Nature Medicine.

[26]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[27]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[28]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[29]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[30]  J. Folkman,et al.  Involvement of platelets in tumour angiogenesis? , 1998, The Lancet.

[31]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[32]  J. Mulliken,et al.  Molecular basis of vascular anomalies. , 1998, Trends in cardiovascular medicine.

[33]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[34]  P. Carmeliet,et al.  Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. , 1998, Thrombosis research.

[35]  G. Garcı́a-Cardeña,et al.  Biological action of leptin as an angiogenic factor. , 1998, Science.

[36]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Rafii,et al.  Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus , 1998, Nature.

[38]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[39]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[40]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[42]  Rakesh K. Jain,et al.  Quantitative angiogenesis assays: Progress and problems , 1997, Nature Medicine.

[43]  R K Jain,et al.  Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.

[44]  Paolo A. Netti,et al.  Solid stress inhibits the growth of multicellular tumor spheroids , 1997, Nature Biotechnology.

[45]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[46]  S. Sallan,et al.  Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. , 1997, The American journal of pathology.

[47]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[48]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[49]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[50]  R. Soldi,et al.  The angiogenesis induced by HIV–1 Tat protein is mediated by the Flk–1/KDR receptor on vascular endothelial cells , 1996, Nature Medicine.

[51]  W. Schaper,et al.  Molecular mechanisms of coronary collateral vessel growth. , 1996, Circulation research.

[52]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[53]  R. Jain,et al.  Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.

[54]  A. Giaccia,et al.  Hypoxic Stress Proteins: Survival of the Fittest. , 1996, Seminars in radiation oncology.

[55]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[56]  I. Fidler,et al.  Modulation of the organ microenvironment for treatment of cancer metastasis. , 1995, Journal of the National Cancer Institute.

[57]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[58]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[59]  F. Pansera.  Fractals and cancer. , 1994, Medical hypotheses.

[60]  R. Jain,et al.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. , 1992, Cancer research.

[61]  J. Folkman,et al.  Angiogenic activity of adipose tissue. , 1988, Biochemical and biophysical research communications.

[62]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[63]  P. Gullino,et al.  Angiogenesis and oncogenesis. , 1978, Journal of the National Cancer Institute.

[64]  M. Knoth,et al.  Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. , 1968, Journal of the National Cancer Institute.

[65]  M. Greenblatt,et al.  Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.

[66]  H. W. Chalkley,et al.  Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants , 1945 .

[67]  E. Goldmann.  The Growth of Malignant Disease in Man and the Lower Animals, with special reference to the Vascular System. , 1907, Proceedings of the Royal Society of Medicine.